### **SUPPLEMENTAL FORM 8 (OPEN POSITIONS)**

# DETAILS OF OPEN STOCK-SETTLED DERIVATIVE (INCLUDING OPTION) POSITIONS, AGREEMENTS TO PURCHASE OR SELL ETC. Note 5(i) on Rule 8 of the Takeover Code (the "Code")

#### 1. KEY INFORMATION

Full name of person making disclosure:	Nomura Holdings Inc.
Name of offeror/offeree in relation to whose relevant securities the disclosure relates:	Takeda Pharmaceutical Company Limited

## 2. STOCK-SETTLED DERIVATIVES (INCLUDING OPTIONS)

Class of relevant security	Product description e.g. call option	Written or purchased	Number of securities to which option or derivative relates	Exercis e price per unit	Type e.g. American, European etc.	Expiry date
Ordinary	Call	Purchased	-6,100	4,910	European	3-Dec-18
Ordinary	Call	Purchased	-21,700	4,847	European	7-Jun-21
Ordinary	Put	Purchased	-11,800	4,460	European	10-Jan-19
Ordinary	Put	Purchased	-6,700	4,450	European	17-Apr-20
Ordinary	Put	Purchased	-6,000	4,727	European	31-July-20
Ordinary	Put	Purchased	-6,500	4,564	European	30-Aug-21
Ordinary	Put	Purchased	-10,300	4,827	European	28-Dec-21
Ordinary	Put	Purchased	-22,900	4,350	European	21-Jun-23
Ordinary	Put	Purchased	-6,400	4,626	European	11-Jul-23
Ordinary	Put	Purchased	-21,000	4,739	European	4-Aug-23
Ordinary	Put	Purchased	-11,400	4,367	European	24-Oct-23

#### 3. AGREEMENTS TO PURCHASE OR SELL ETC.

Full details should be given so that the nature of the interest or position can be funderstood:	ully

It is not necessary to provide details on a Supplemental Form (Open Positions) with regard to cash-settled derivatives.

The currency of all prices and other monetary amounts should be stated.

The Panel's Market Surveillance Unit is available for consultation in relation to the Code's disclosure requirements on +44 (0)20 7638 0129.

The Code can be viewed on the Panel's website at <a href="www.thetakeoverpanel.org.uk">www.thetakeoverpanel.org.uk</a>.